✨ Your Portfolio is fetched and updated from zerodha.
Micro Pharmaceuticals

Kilitch Drugs (India) Ltd.

KILITCH

Market Cap
₹549 Cr.
P/E
28.12

Kilitch Drugs (India) Ltd.

  • Kilitch Drugs(India)
  • Medicamen Biotech
  • Prevest Denpro
FAQs on Kilitch Drugs (India) Ltd. Shareprice

Kilitch Drugs(India) has given better returns compared to its competitors.
Kilitch Drugs(India) has grown at ~22.7% over the last 3yrs while peers have grown at a median rate of 11.84%

Kilitch Drugs(India) is not expensive.
Latest PE of Kilitch Drugs(India) is 28.12, while 3 year average PE is 55.22.
Also latest EV/EBITDA of Kilitch Drugs(India) is 24.41 while 3yr average is 32.03.

View FAQ's On Business
Growth Table
  • Kilitch Drugs (India) Ltd.
  • Medicamen Biotech
  • Prevest Denpro
Balance Sheet
  • Kilitch Drugs (India) Ltd.
  • Medicamen Biotech
  • Prevest Denpro
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Kilitch Drugs (India) Ltd.
  • Medicamen Biotech
  • Prevest Denpro
Cash Flow
  • Kilitch Drugs (India) Ltd.
  • Medicamen Biotech
  • Prevest Denpro
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Kilitch Drugs (India) Ltd.
  • Medicamen Biotech
  • Prevest Denpro
Quarterly Results
  • Kilitch Drugs (India) Ltd.
  • Medicamen Biotech
  • Prevest Denpro
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Rhapson method.
Learn how to use Reverse DCF
FAQs on Kilitch Drugs (India) Ltd. Financials

Balance sheet of Kilitch Drugs(India) is strong.
It shouldn't have solvency or liquidity issues.

Yes, The debt of Kilitch Drugs(India) is increasing.
Latest debt of Kilitch Drugs(India) is ₹26.14 Crs as of Sep-24.
This is greater than Mar-24 when it was -₹7.63 Crs.

Yes, profit is increasing.
The profit of Kilitch Drugs(India) is ₹18.02 Crs for TTM, ₹14.6 Crs for Mar 2024 and ₹10.45 Crs for Mar 2023.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Kilitch Drugs(India) latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments, Accounts Receivable

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech